ALTO-100 is under clinical development by Alto Neuroscience and currently in Phase II for Major Depressive Disorder. According to GlobalData, Phase II drugs for Major Depressive Disorder have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ALTO-100’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ALTO-100 is under development for the treatment of post-traumatic stress disorder (PTSD) and major depressive disorder (MDD). It is developed based on artificial intelligence (AI)-based brain biomarker platform and Precision Psychiatry Platform. It is administered through oral route. It acts by targeting BDNF.
Alto Neuroscience overview
Alto Neuroscience is a biopharmaceutical company that develops drugs for psychiatric and mental health conditions. It is investigating ALTO-100, ALTO-202, and ALTO-300 drugs for the treatment of major depressive disorder (MDD) and post-traumatic stress disorder (PTSD) by targeting cognition, emotion and sleep systems. The company utilizes its AI-enabled drug development platform that identifies biomarkers by evaluating brain function measures to develop its product candidates. Alto Neuroscience is headquartered in Los Altos, California, the US.
For a complete picture of ALTO-100’s drug-specific PTSR and LoA scores, buy the report here.